ArticleThoracic cancer2025
Impact of Exposure to Benzodiazepines on Adverse Effects and Efficacy of PD-1/PD-L1 Blockade in Patients With Non-Small Cell Lung Cancer.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neutralization of acyl-CoA-binding protein attenuates glucocorticoid-mediated suppression of cancer immunosurveillance.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Stress management by benzodiazepines in septic shock and critical illness: mechanistic and clinical evidence supporting alternative sedative strategies.Cell stress · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundThe impact of concomitant medications on immune-related adverse events (irAEs) and immune checkpoint inhibitor (ICI) efficacy in non-small cell lung cancer (NSCLC) remains unclear. Benzodiazepine receptor agonists (BZRAs), commonly prescribed for anxiety and insomnia in cancer care, may influence antitumor immunity via γ-aminobutyric acid (GABA) signaling. Here, we retrospectively analyzed medical records of NSCLC patients treated with ICIs.
methodsIn an initial exploratory analysis, BZRA use was significantly associated with a lower incidence of irAEs, prompting further evaluation. Propensity score matching (PSM) was performed to adjust for potential confounding factors. In the matched cohort, we assessed associations between BZRA use, irAE incidence, and ICI efficacy, as measured by progression-free survival (PFS) and overall survival (OS).
resultsIn the matched cohort, BZRA use was significantly associated with a lower incidence of irAEs (OR 0.33, 95% CI: 0.13-0.80, p = 0.015). BZRA use was also linked to shorter PFS (HR 1.80, 95% CI: 1.13-2.86, p = 0.013), but not OS (HR 1.63, 95% CI: 0.95-2.81, p = 0.077). In subgroup analysis, among patients who developed irAEs, BZRA use was associated with shorter PFS (HR 2.69, 95% CI: 1.32-5.48, p = 0.007) and OS (HR 3.35, 95% CI: 1.40-8.04, p = 0.007), whereas no significant associations were observed in non-irAE patients.
conclusionBZRA use was associated with reduced irAE incidence and poorer ICI outcomes among patients who developed irAEs, suggesting potential immunosuppressive effects that may impair ICI efficacy in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.